Hematologic modifications in natalizumab-treated multiple sclerosis patients
An 18-month longitudinal study
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received December 22, 2014
- Accepted in final form March 30, 2015
- First Published June 18, 2015.
Author Disclosures
- Claire Bridel, MD, PhD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yan Beauverd, MD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kaveh Samii, MD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Patrice H. Lalive, MD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Clinical Neurosciences (C.B., P.H.L.), Division of Neurology, Unit of Neuroimmunology and Multiple Sclerosis; Department of Hematology (Y.B., K.S.); and Department of Genetics and Laboratory Medicine (P.H.L.), Laboratory Medicine Service, University Hospital of Geneva, Switzerland.
- Correspondence to Prof. Lalive: patrice.lalive{at}hcuge.ch
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patientsTatiana Plavina, Kumar Kandadi Muralidharan, Geoffrey Kuesters et al.Neurology, September 15, 2017 -
Article
Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarateCollin M. Spencer, Elizabeth C. Crabtree-Hartman, Klaus Lehmann-Horn et al.Neurology - Neuroimmunology Neuroinflammation, February 12, 2015 -
Articles
Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MSM.C. Kowarik, H.L. Pellkofer, S. Cepok et al.Neurology, April 04, 2011 -
Articles
Hypereosinophilia in patients with multiple sclerosis treated with natalizumabM. Abbas, P.H. Lalive, M. Chofflon et al.Neurology, October 05, 2011